Skip to content

Clinical trials

Terminated Major Depressive Disorder trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Major Depressive Disorder Status: Terminated Clear all

187 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20032
20043
20054
20063
20076
200812
20094
201016
201110
201211
201315
20147
20153
201610
201711
201812
201913
20208
20219
20227
20234
202410
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated187

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Janssen Research & Development, LLC9
Massachusetts General Hospital8
New York State Psychiatric Institute7
Naurex, Inc, an affiliate of Allergan plc6
Otsuka Pharmaceutical Development & Commercialization, Inc.6
National Institute of Mental Health (NIMH)5
H. Lundbeck A/S4
University of Texas Southwestern Medical Center4
AstraZeneca3
Pfizer3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Major Depressive Disorder187
Depressive Disorder18
Bipolar Disorder11
Depressive Disorder, Treatment-Resistant11
Mood Disorders8
Stress Disorders, Post-Traumatic8
Anxiety Disorders5
Generalized Anxiety Disorder4
Mental Disorders4
Obsessive-Compulsive Disorder4

Trials

Showing 76 to 100 of 187. Each trial links to its page on Pharma Observatory.

87 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.